New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:06 EDTARNAArena Pharmaceuticals initiates Phase 1b clinical trial of APD334
Arena Pharmaceuticals announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
July 16, 2014
09:37 EDTARNAActive equity options trading on open
Subscribe for More Information
July 15, 2014
16:34 EDTARNAArena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators
Arena Pharmaceuticals announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the U.S. Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2. Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
10:40 EDTARNAArena Pharmaceuticals receives USPTO patent for cannabinoid receptor modulators
Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use